Using the biosimilar resulted in a significantly lower drug acquisition cost, at $533.40 in the biosimilar group versus $1261.90 in the reference group.
In autologous stem cell transplantation, mobilization of peripheral blood stem cells (PBSCs) is crucial, and the use of granulocyte colony-stimulating factor (G-CSF) therapies plays a key role in ensuring success. Lower-cost biosimilar G-CSF agents may be a way to reduce the overall cost of treatment, and in a recent study in a single center in Singapore, researchers found that a biosimilar filgrastim, Pfizer’s Nivestim (sold in the US market as Nivestym), was safe and noninferior to its reference, Neupogen, in mobilizing stem cells for autologous stem cell transplantation.
In the study, all patients who underwent autologous stem cell transplantation between 2011 and 2016 were included in the retrospective cohort. Those treated up to March 2014 (n = 66) had received the reference filgrastim, while those treated afterward received the biosimilar (n = 65). Patient characteristics were similar with the exception of chemo-mobilization regimen.
The primary outcome of the study was the proportion of patients who had successful mobilization, which was defined as a harvest of at least 2 × 106 CD34+ cells per kilogram of bodyweight.
In the biosimilar group and the reference group, mobilization was successful in 96.9% and 97% of patients, respectively (P = .988). The authors noted that the number of CD34+ cells mobilized was higher in the biosimilar group, although the difference did not achieve statistical significance. Safety was also similar; the incidence and severity of adverse events were comparable between the groups, with headache, back pain, and bone pain being the most commonly reported.
Notably, the median length of hospital stay required for mobilization was significantly shorter in the biosimilar group (15 days) than in the reference group (17 days), and the duration of G-CSF use per mobilization was lower in the biosimilar group (9 days) than in the reference group (10 days).
Using the biosimilar also resulted in a significantly lower drug acquisition cost, at $533.40 in the biosimilar group versus $1261.90 in the reference group (P <.0001).
According to the authors, using the biosimilar to mobilize stem cells was both safe and noninferior to using the reference filgrastim, and results in a lower drug cost and a potentially shorter length of hospitalization.
Reference
Chew C, Ng HY. Efficacy and safety of Nivestim versus Neupogen for mobilization of peripheral blood stem cells for autologous stem cell transplantation [published online December 27, 2019]. Sci Rep. 2019. doi: 10.1038/s41598-019-56477-w.
Cencora Analysis Shows Differences in Payer Coverage Between G-CSF Biosimilars
May 2nd 2024Data from a Cencora study showed some misalignment in payer coverage of granulocyte colony-stimulating factor (G-CSF) biosimilars, highlighting that while filgrastim biosimilars are often favored over the originator, reference pegfilgrastim still dominates over its biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.
AON Saves Over $243 Million With High Biosimilar Adoption
April 22nd 2024Thanks to high biosimilar adoption rates within the community oncology setting, American Oncology Network (AON) saved upwards of $243 million between 2020 and 2023, according to a presentation at the Festival of Biologics USA conference in San Diego, California.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.